+

WO2000056891A3 - Proteines transmembranaires humaines - Google Patents

Proteines transmembranaires humaines Download PDF

Info

Publication number
WO2000056891A3
WO2000056891A3 PCT/US2000/007817 US0007817W WO0056891A3 WO 2000056891 A3 WO2000056891 A3 WO 2000056891A3 US 0007817 W US0007817 W US 0007817W WO 0056891 A3 WO0056891 A3 WO 0056891A3
Authority
WO
WIPO (PCT)
Prior art keywords
transmembrane proteins
htmp
human transmembrane
provides
expression
Prior art date
Application number
PCT/US2000/007817
Other languages
English (en)
Other versions
WO2000056891A2 (fr
Inventor
Henry Yue
Preeti Lal
Y Tom Tang
Jennifer L Hillman
Roopa Reddy
Olga Bandman
Mariah R Baughn
Dyung Aina M Lu
Yalda Azimzai
Junming Yang
Original Assignee
Incyte Pharma Inc
Henry Yue
Preeti Lal
Y Tom Tang
Jennifer L Hillman
Roopa Reddy
Olga Bandman
Mariah R Baughn
Dyung Aina M Lu
Yalda Azimzai
Junming Yang
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Incyte Pharma Inc, Henry Yue, Preeti Lal, Y Tom Tang, Jennifer L Hillman, Roopa Reddy, Olga Bandman, Mariah R Baughn, Dyung Aina M Lu, Yalda Azimzai, Junming Yang filed Critical Incyte Pharma Inc
Priority to CA002365243A priority Critical patent/CA2365243A1/fr
Priority to EP00918335A priority patent/EP1210419A2/fr
Priority to JP2000606750A priority patent/JP2003525025A/ja
Priority to AU39164/00A priority patent/AU3916400A/en
Publication of WO2000056891A2 publication Critical patent/WO2000056891A2/fr
Publication of WO2000056891A3 publication Critical patent/WO2000056891A3/fr
Priority to US10/187,657 priority patent/US7105315B2/en
Priority to US11/498,712 priority patent/US20060275314A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Communicable Diseases (AREA)
  • Gynecology & Obstetrics (AREA)
  • Virology (AREA)
  • Cardiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Molecular Biology (AREA)

Abstract

L'invention concerne des protéines transmembranaires humaines (HTMP) et des polynucléotides qui identifient et codent pour HTMP; des vecteurs d'expression, des cellules hôtes, des anticorps, des agonistes et des antagonistes; et des méthodes permettant de diagnostiquer, de traiter ou de prévenir les troubles associés à l'expression de HTMP.
PCT/US2000/007817 1999-03-22 2000-03-22 Proteines transmembranaires humaines WO2000056891A2 (fr)

Priority Applications (6)

Application Number Priority Date Filing Date Title
CA002365243A CA2365243A1 (fr) 1999-03-22 2000-03-22 Proteines transmembranaires humaines
EP00918335A EP1210419A2 (fr) 1999-03-22 2000-03-22 Proteines transmembranaires humaines
JP2000606750A JP2003525025A (ja) 1999-03-22 2000-03-22 ヒト膜貫通タンパク質
AU39164/00A AU3916400A (en) 1999-03-22 2000-03-22 Human transmembrane proteins
US10/187,657 US7105315B2 (en) 1999-06-16 2002-07-01 Transmembrane protein differentially expressed in cancer
US11/498,712 US20060275314A1 (en) 1999-03-22 2006-08-04 Transmembrane protein differentially expressed in cancer

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US12553799P 1999-03-22 1999-03-22
US60/125,537 1999-03-22
US13956599P 1999-06-16 1999-06-16
US60/139,565 1999-06-16

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US10/187,657 Continuation-In-Part US7105315B2 (en) 1999-03-22 2002-07-01 Transmembrane protein differentially expressed in cancer

Publications (2)

Publication Number Publication Date
WO2000056891A2 WO2000056891A2 (fr) 2000-09-28
WO2000056891A3 true WO2000056891A3 (fr) 2001-04-05

Family

ID=26823669

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/007817 WO2000056891A2 (fr) 1999-03-22 2000-03-22 Proteines transmembranaires humaines

Country Status (5)

Country Link
EP (1) EP1210419A2 (fr)
JP (1) JP2003525025A (fr)
AU (1) AU3916400A (fr)
CA (1) CA2365243A1 (fr)
WO (1) WO2000056891A2 (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1165778E (pt) 1999-03-11 2007-01-31 Glaxosmithkline Biolog Sa Utilizações de polinucleótidos e polipéptidos casb618
WO2000070076A1 (fr) * 1999-05-19 2000-11-23 Human Genome Sciences, Inc. Recepteurs tm4sf
AU7728100A (en) * 1999-09-28 2001-04-30 Zymogenetics Inc. Membrane-bound protein-60
US20030185814A1 (en) * 2000-01-27 2003-10-02 Kay Hofmann Ceramidase
CA2406058A1 (fr) * 2000-04-10 2001-10-18 Human Genome Sciences, Inc. Anticorps, polypeptides et polynucleotides du recepteur tm4sf
WO2002016603A2 (fr) * 2000-08-21 2002-02-28 Millennium Pharmaceuticals, Inc. 23228, nouveau membre de la famille des tetraspanines humaines, et utilisations correspondantes
CA2409164A1 (fr) * 2000-05-18 2001-11-22 Hyseq, Inc. Nouveaux acides nucleiques et polypeptides
JP2004530409A (ja) * 2000-10-27 2004-10-07 インサイト・ゲノミックス・インコーポレイテッド 膜貫通タンパク質
EP1491628A4 (fr) * 2002-03-29 2006-10-18 Nat Inst Of Advanced Ind Scien Nouvelles galactose transferases et leurs peptides, et acide nucleique codant pour lesdites transferases
JPWO2005017155A1 (ja) 2003-06-18 2006-10-12 中外製薬株式会社 フコーストランスポーター
CA2949753A1 (fr) * 2005-12-22 2007-07-05 Abbott Molecular Inc. Procede et combinaisons de marqueurs permettant de depister une predisposition au cancer du poumon
EP2814979A1 (fr) * 2012-02-17 2014-12-24 Fundación Centro Nacional De Investigaciones Oncológicas Carlos III Homologues mammifères de flower, leur utilisation dans le diagnostic, la prévention et le traitement du cancer

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0834563A2 (fr) * 1996-09-26 1998-04-08 Smithkline Beecham Corporation Récepteur transmembranaire humain, membre de la famille des récepteurs de chémokines, appelé aussi Strl-33

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0834563A2 (fr) * 1996-09-26 1998-04-08 Smithkline Beecham Corporation Récepteur transmembranaire humain, membre de la famille des récepteurs de chémokines, appelé aussi Strl-33

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
HAMMOND H.A. ET AL.: "Homo sapiens chromosome 11 clone pac255-m-19 map 11q13,***sequencing in progress***, 7 ordered pieces", EMBL DATABASE SEQUENCE AC024127;ACCESSION NO. AC024127, 24 February 2000 (2000-02-24), XP002148958 *
NCI-CGAP: "National Cancer Institute, Cancer Genome Anatomy Project (CGAP), Tumor Gene Index http://www.ncbi.nlm.nih.gov/ncicgap; ot03c01.s1 NCI_CGAP_GC3 Homo sapiens cDNA clone IMAGE:1613760 3', mRNA sequence", EMBL DATABASE ENTRY AI000010; ACCESSION NO. AI000010, 5 June 1998 (1998-06-05), XP002148959 *

Also Published As

Publication number Publication date
WO2000056891A2 (fr) 2000-09-28
CA2365243A1 (fr) 2000-09-28
EP1210419A2 (fr) 2002-06-05
JP2003525025A (ja) 2003-08-26
AU3916400A (en) 2000-10-09

Similar Documents

Publication Publication Date Title
WO1999061471A3 (fr) Proteines transmembranaires humaines
WO2001012662A3 (fr) Proteines associees a la membrane
WO2000015793A3 (fr) Proteines gpcr humaines
WO2000018922A8 (fr) Proteines humaines associees a des glucides
WO2000034477A3 (fr) Proteines associees a des neurones
WO2000021988A3 (fr) Proteine humaine de la famille des ankyrines
WO1999058692A3 (fr) Proteines associees a l'apoptose humaine
WO2000026245A3 (fr) Proteines de transport membranaire
WO2000017355A3 (fr) Proteines humaines associees au cytosquelette
WO2001020004A3 (fr) Proteines phosphatase et proteines kinase
WO2001007612A3 (fr) Recepteurs et proteines associees
WO2000014251A3 (fr) Transferases humaines
WO2001005970A3 (fr) Proteines associees de liaison gtp
WO2000052151A3 (fr) Proteines de secretion humaines
WO2000056891A3 (fr) Proteines transmembranaires humaines
WO2000044900A3 (fr) Proteines liant des acides nucleiques
WO2000000594A3 (fr) Transferases humaines
WO1999061614A3 (fr) Proteines socs humaines
WO2001044448A3 (fr) Proteines d'oxydoreductase humaines
WO2002034783A3 (fr) Proteines transmembranaires
WO2000031263A3 (fr) Proteines associees a la gtpase
WO2000028045A3 (fr) Hydrolases humaines
WO2000065054A3 (fr) Proteines humaines associees aux membranes
WO2000001821A3 (fr) Proteines associees a la neurotransmission
WO2000008155A3 (fr) Proteines associees a un recepteur humain

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

ENP Entry into the national phase

Ref document number: 2365243

Country of ref document: CA

Ref country code: CA

Ref document number: 2365243

Kind code of ref document: A

Format of ref document f/p: F

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2000 606750

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 2000918335

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWE Wipo information: entry into national phase

Ref document number: 09937059

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 2000918335

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 10187657

Country of ref document: US

WWW Wipo information: withdrawn in national office

Ref document number: 2000918335

Country of ref document: EP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载